Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer?

Pharmacol Res. 2023 Jan:187:106619. doi: 10.1016/j.phrs.2022.106619. Epub 2022 Dec 16.

Authors

Dimitrios Patoulias¹, George Kassimis², Nikolaos Fragakis²

Affiliations

¹ Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece. Electronic address: [email protected].
² Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.

PMID: 36535570
DOI: 10.1016/j.phrs.2022.106619

No abstract available

Publication types

Letter

MeSH terms

Atherosclerosis* / drug therapy
Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2*
Gastrointestinal Microbiome*
Glucose
Humans
Hypoglycemic Agents
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Symporters*

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents
Symporters
Glucose
Sodium